1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Sarilumab
Trade Name:
Kevzara
Manufacturer/Distributor:
Sanofi Genzyme Canada
Classification:
Disease modifying anti-rheumatic drug
ATC Class:
L04AC - Interleukin inhibitor
Status:
active
Notice of Compliance (yyyy/mm/dd):
2017/05/30
Date Marketed in Canada (yyyy/mm/dd):
2017/08/16
Presentation:
Injection: 150 mg/1.14 mL. DIN: 02460521
Injection: 200 mg/1.14 mL. DIN: 02460548
Comments:
Sarilumab is an interleukin-6 receptor antibody for treatment of adults with moderate to severe rheumatoid arthritis who have had either an intolerance or inadequate response to one or more DMARDs. The recommended dose of is 200 mg once every 2 weeks given as a subcutaneous injection. Reduction of dose from 200 mg once every 2 weeks to 150 mg once every 2 weeks is recommended for management of neutropenia, thrombocytopenia, and elevated liver enzymes.
Back to:
Drug Product Listings 
